Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 9128 results

  1. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    In development Reference number: GID-TA11956 Expected publication date:  28 January 2027

    Technology appraisal guidance
    In development

  3. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]

    In development Reference number: GID-TA11996 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  5. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549

    In development Reference number: GID-TA11722 Expected publication date:  20 May 2027

    Technology appraisal guidance
    In development

  6. Nemolizumab for treating prurigo nodularis [ID6451]

    In development Reference number: GID-TA11566 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  8. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date:  17 March 2027

    Highly specialised technologies guidance
    In development

  9. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  18 February 2027

    Quality standard
    In development

  10. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  11. Vertebral body tethering for idiopathic scoliosis in children and young people

    Awaiting development Reference number: GID-HTG10657 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation

    Awaiting development Reference number: GID-TA12036 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 years

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Semaglutide 7.2 mg dose for managing obesity ID6699

    In development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    In development